Testing effectiveness (Phase 2)Study completedNCT05067582
What this trial is testing
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
Who this might be right for
Autism Spectrum DisorderAutism
Yamo Pharmaceuticals LLC 58